INSPIRE (INcreased Sun exposure without Pain In Research subjects with EPP).
- Conditions
- Erythropoietic Protoporphyria or X-Linked ProtoporphyriaMedDRA version: 21.1Level: LLTClassification code: 10015289Term: Erythropoietic protoporphyria Class: 10010331Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]
- Registration Number
- CTIS2023-506735-15-00
- Lead Sponsor
- Mitsubishi Tanabe Pharma America Inc.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 150
Subjects provided written informed consent to participate. For minor subjects, both minor’s assent and legal representative´s consent will be required., Male and female subjects with a confirmed diagnosis of EPP or XLP based on medical history., Subjects aged 12 years to 75 years, inclusive, at Screening., Subjects are willing and able to travel to the study sites for all scheduled visits., In the Investigator’s opinion, subject can understand the nature of the study and any risks involved in participation, and willing to cooperate and comply with the protocol restrictions and requirements (including travel and receiving direct sunlight exposure as much as possible)., Female subjects who are non-lactating and have a negative urine pregnancy test at baseline visit prior to receiving the first dose of study drug., Female subjects of childbearing potential and male subjects with partner of childbearing potential currently using/willing to use 2 effective methods of contraception
History or presence of photodermatoses other than EPP or XLP., Previous treatment with any investigational agent such as bitopertin within 12 weeks before Screening OR 5 half-lives of the investigational product (whichever is longer)., Subjects who are unwilling or unable to go outside in sunlight during daylight hours most days (e.g., between 1-hour post-sunrise and 1 hour pre-sunset) during the study., Use of sunscreens with zinc oxide., Presence or history of any hepatobiliary disease, including drug-induced liver injury at screening, determined as clinically significant by the Investigator after the discussion with the Sponsor Medical Monitor., Subjects with Aspartate aminotransferase (AST), Alanine aminotransferase (ALT), Alkaline phosphatase (ALP) = 2.0 × upper limit of normal (ULN) or total bilirubin >1.5 × ULN at Screening., History (in the last 2 years) or presence of alcohol abuse, or abuse of illicit drugs in the opinion of the Investigator., History of melanoma., Presence of squamous cell carcinoma, basal cell carcinoma, or other malignant skin lesions. Any suspicious lesions or nevi will be evaluated. If the suspicious lesion or nevi cannot be resolved through biopsy or excision, the subject will be excluded from the study., History or presence of psychiatric disease judged to be clinically significant by the Investigator and which may interfere with the study evaluation and/or safety of the subjects., Presence of clinically significant acute or chronic renal disease or subjects with an estimated glomerular filtration rate (eGFR) <60 mL/min as calculated by the Chronic Kidney Disease-Epidemiology Collaboration (CKD-EPI) creatinine equation (2021) for adults and by the Schwartz creatinine equation for adolescents (2009). Modification of Diet in Renal Disease can be used for adults per local recommendations., Presence of any clinically significant disease or laboratory abnormality which, in the opinion of the Investigator, can interfere with the study objectives and/or safety of the subjects., Female subjects who are pregnant, lactating, or intending to become pregnant during the study., Treatment with any of the following medications or therapy within each period before Randomization (Visit 2): - Afamelanotide within 3 months; - Phototherapy within 3 months; - Cimetidine within 4 weeks; - Antioxidant agents within 4 weeks; - Chronic treatment with any scheduled analgesic agents., Dermatological treatments with any drugs or supplements which, in the opinion of the Investigator, can interfere with the objectives of the study or safety of the subjects at screening such as, for example, tanning agents., Subjects who participated in any previous MT-7117 clinical studies.
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Main Objective: To investigate the efficacy of MT-7117 on time to onset and severity of first prodromal symptoms (burning, tingling, itching, or stinging) associated with sunlight exposure in adults and adolescents with Erythropoietic protoporphyria (EPP) or X-linked protoporphyria (XLP).;Secondary Objective: To investigate the effect on Patient Global Impression of Change (PGIC) in adults and adolescents with EPP or XLP., To investigate the effect on number of sunlight-induced pain events (prodrome and phototoxic reactions) in adults and adolescents with EPP or XLP.;Primary end point(s): Change from baseline in average daily sunlight exposure time (in minutes) to first prodromal symptom (burning, tingling, itching, or stinging) associated with sunlight exposure between 1-hour post-sunrise and 1 hour pre-sunset at Week 16.
- Secondary Outcome Measures
Name Time Method Secondary end point(s):Patient Global Impression of Change (PGIC) at Week 16.;Secondary end point(s):Total number of sunlight-induced pain events defined as prodromal symptoms (burning, tingling, itching, or stinging) with pain rating of 1-10 on the Likert scale during the 16-week double-blind treatment period.;Secondary end point(s):Total number of sunlight-induced non-prodrome, phototoxic reactions during the 16-week double-blind treatment period.